BridgeMD
The MiBlock study
EU CTIS ID: 2024-515165-34-00
What this study is testing
The primary objective is to determine the efficacy of treatment with botulinum toxin towards the sphenopalatine ganglion (SPG) in treatment refractory chronic migraine using an image-guided surgical device (MultiGuide®).
- Therapeutic confirmatory (Phase III)
A plain-language read of the study's public EU CTIS listing. The study team confirms the details.
Who can take part
You may be able to join if
- Informed and written consent
- In the case of women of childbearing potential (WOCBP) they have to commit to highly effective contraception in a period of 4 weeks after injection (for details, confer section 4.3)
- Ability to understand study procedures and to comply with them for the entire length of the study
- Male or female, between 18 and 70 years of age
- Masters a Scandinavian language at level sufficient to fully understand the written and verbal study information
- Migraine, with or without aura, fulfilling the International Classification of Headache Disorders (ICHD) III criteria 1.3. for chronic migraine at time of inclusion
You likely can't join if
- Allergy or hypersensitivity reactions to marcaine, lidocaine, xylocaine, adrenaline, any botulinum toxin or similar substances.
- Subject is currently participating or has participated in the last 3 months in another clinical study in which the subject has, is, or will be exposed to an investigational or non-investigational drug or device.
- Subject has had previous radiofrequency ablation, balloon compression, gamma knife, or chemical denervation (e.g. glycerol treatments) of the trigeminal ganglion or any branch of the trigeminal nerve.
- Subject has had previous radiofrequency ablation (including non-lesional pulsed radiofrequency), balloon compression, gamma knife, or chemical denervation (e.g. glycerol treatments) of the SPG.
- Subject has had blocks of short-acting anaesthetics of the SPG in the last 3 months.
- Subject is or has been treated with occipital nerve stimulation or deep brain stimulation.
See the full eligibility criteria
Who can join
- Informed and written consent
- In the case of women of childbearing potential (WOCBP) they have to commit to highly effective contraception in a period of 4 weeks after injection (for details, confer section 4.3)
- Ability to understand study procedures and to comply with them for the entire length of the study
- Male or female, between 18 and 70 years of age
- Masters a Scandinavian language at level sufficient to fully understand the written and verbal study information
- Migraine, with or without aura, fulfilling the International Classification of Headache Disorders (ICHD) III criteria 1.3. for chronic migraine at time of inclusion
- Chronic migraine at least for a period of 1 year prior to inclusion
- Debut of episodic migraine before the age of 50, and chronic migraine before the age of 65.
- The condition is pharmacologically refractory as defined in this study as insufficient treatment effect, contraindication(s) or intolerable side effect(s) of at least 3 medications from at least 2 of the following medication (drug) classes a. Beta-blockers b. RA(A)S-inhibitors c. Calcium-antagonists d. Antiepileptic drugs e. Tricyclic antidepressants f. Botulinum toxin A g. CGRP antagonists
- Subject has had no change in type, dosage or dose frequency of preventive headache medications < 3 months prior to baseline/screening, or a minimum of 5 half-lives, whichever is longer.
- Subject agrees to maintain current preventive headache medication regimens (no change in type, frequency, or dose) during the whole study period.
What rules you out
- Allergy or hypersensitivity reactions to marcaine, lidocaine, xylocaine, adrenaline, any botulinum toxin or similar substances.
- Subject is currently participating or has participated in the last 3 months in another clinical study in which the subject has, is, or will be exposed to an investigational or non-investigational drug or device.
- Subject has had previous radiofrequency ablation, balloon compression, gamma knife, or chemical denervation (e.g. glycerol treatments) of the trigeminal ganglion or any branch of the trigeminal nerve.
- Subject has had previous radiofrequency ablation (including non-lesional pulsed radiofrequency), balloon compression, gamma knife, or chemical denervation (e.g. glycerol treatments) of the SPG.
- Subject has had blocks of short-acting anaesthetics of the SPG in the last 3 months.
- Subject is or has been treated with occipital nerve stimulation or deep brain stimulation.
- Ongoing abuse of drugs (including narcotics) or alcohol.
- More than 4 days of opioid use per month (including codeine and tramadol), and any use of barbiturates
- Treatment with pharmacological substances prior to SPG-injection that may interact with BTA (aminoglycosides, spectinomycin, neuromuscular blockers, both depolarizing agents (such as succinylcholine) or non-depolarizing (tubocurarine derivates), and anticholinesterases).
- Inadequate contraceptive use. Women of childbearing potential (WOCBP) who do not use highly effective contraception (HEC) or use other medication that may interact and/or otherwise reduce the efficacy of the contraceptiva in use.
- Subject has undergone facial surgery in the area of the pterygopalatine fossa or zygomaticomaxillary at the planned injection site that, in the opinion of the Investigator, may lead to an inability to properly conduct the procedure.
- Subject is unable to differentiate migraine from other concomitant headaches.
- Facial anomaly or trauma which renders the procedure difficult.
- Subject currently has an active oral or dental abscess or a local infection at the site of injection based on present symptoms.
- Subject has been diagnosed with any major infectious processes such as osteomyelitis, or primary or secondary malignancies involving the face that have been active or required treatment in the past 6 months.
- Patients with comorbid psychiatric disorders with psychotic or other symptoms making compliance with the study protocol difficult, at the discretion of the investigator
- Patients exhibiting a high degree of comorbidity and/or frailty associated with reduced life expectancy or high likelihood of hospitalization, at the discretion of the investigator
- Patients with disorders that severely inhibits lacrimation, at the discretion of the investigator
- Patients with previous ischemic cardiovascular and cerebrovascular disorder with, in the opinion of the investigator, a moderate to high risk of new ischemic episodes.
- Known infection or history of human immunodeficiency virus, tuberculosis, or chronic hepatitis B or C infection.
- Subject has a history of bleeding disorders or coagulopathy, that, in the opinion of the Investigator, may lead to an inability to properly conduct the procedure.
- Unable to stop antithrombotic medication e.g. platelet aggregation inhibitors and/or anticoagulation therapy, prior to procedure.
- Subject with secondary headache conditions, with the exception of medication overuse headache.
- The patient cannot participate or successfully complete the study, in the opinion of their healthcare provider or the investigator, for any of the following reasons: • mentally or legally incapacitated or unable to give consent for any reason • in custody due to an administrative or a legal decision, under tutelage, or being admitted to a sanatorium or social institution • has any other condition, which, in the opinion of the investigator, makes the patient inappropriate for inclusion in the study
- The patient is a study centre employee who is directly involved in the study or the relative of such an employee.
- Non-responder in regular clinical practice to preventive medications from ≥6 of the following 7 drug classes: a. Beta-blockers b. RA(A)S-inhibitors c. Calcium-antagonists d. Antiepileptic drugs e. Tricyclic antidepressants f. Botulinum toxin A g. CGRP antagonists
- Subject has had a change in type, dosage or dose frequency of preventive headache medications < 3 months prior to baseline/screening, or a minimum of 5 half-lives, whichever is longer.
- Subject has had a change in type, dosage or dose frequency of preventive headache medications during the baseline period, eg. prior to IMP administration
- Botulinum toxin injections in the head and neck region, as part of migraine treatment or otherwise indicated on medical or cosmetic grounds, in the last 4 months before inclusion.
- The discontinuation of CGRP-antagonists within 3 months before study inclusion or 5 half-lives, whichever is longer.
- Participation in a clinical study of a new chemical entity or a prescription medicine within 2 months before study inclusion or 5 half-lives, whichever is longer.
The study team makes the final eligibility decision.
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18-64 years, 65+ years. The study team makes the final eligibility decision.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from EU CTIS; the study team decides eligibility.